Prognostic value of some ovarian reserve tests in poor responders.
BACKGROUND
The objective of this study was to determine the prognostic value of the basal estradiol (E2) and inhibin-B levels, the antral follicle count (AFC), and the clomiphene citrate challenge test (CCCT) of ovarian response in controlled ovarian hyperstimulation (COH), in an outcome with normal follicle-stimulating hormone (FSH) concentration in the early follicular phase of the menstrual cycle.


METHODS
Fifty-two patients undergoing IVF treatment were included in the study. Blood samples were collected for assessment of basal E2, FSH, and inhibin-B levels. Transvaginal ultrasound of an unstimulated cycle was performed to determine the mean antral follicle count (AFC). Serum FSH concentration was measured again on day 10 for CCCT performance.


RESULTS
The mean values of women's age, and basal and day 10 FSH levels were significantly higher in cancelled cycles than in the control group, whereas basal inhibin-B and AFC were significantly higher in the latter. The mean basal E2 concentration was similar in both groups. The results from the logistic regression analysis show that CCCT (cut-off point FSH > 12.5 mIU/ml; AUCROC = 0.90) was a better single predictor of poor ovarian response than AFC (AUCROC = 0.85) and inhibin-B (AUCROC = 0.79) with a correct prediction for CCCT (86.5%), antral follicle count (84.6%), and for inhibin-B (82.7%).


CONCLUSIONS
In women with normal basal FSH level, the determination of E2 has no prognostic value for the outcome of poor responders. However, CCCT, AFC, and inhibin-B tests, when applied separately, produce good prognostic values. CCCT is the best single predictor of poor ovarian response, followed by antral follicle count and basal inhibin-B values. In spite of that, CCCT does not add significantly to the simpler AFC ultrasound test in the prediction of poor ovarian response.
Vladimirov
Iavor K
IK
Medical Faculty, Chair of Obstetrics and Gynecology, 2 Zdrave Street, Sofia, Bulgaria.
Tacheva
Desislava M
DM
Kalinov
Krassimir B
KB
Ivanova
Aneta V
AV
Blagoeva
Victoria D
VD
D000328:Adult; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D016022:Case-Control Studies; D002996:Clomiphene; D004958:Estradiol / Q000097:blood*; D004965:Estrogen Antagonists; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D007265:Inhibins / Q000097:blood*; D016015:Logistic Models; D006080:Ovarian Follicle / Q000000981:diagnostic imaging / Q000187:drug effects; D010050:Ovarian Function Tests / Q000379:methods* / Q000592:standards; D010053:Ovary / Q000000981:diagnostic imaging / Q000187:drug effects / Q000502:physiology*; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D016896:Treatment Outcome; D014463:Ultrasonography
D015415:Biomarkers; D004965:Estrogen Antagonists; D002996:Clomiphene; D004958:Estradiol; D007265:Inhibins; D005640:Follicle Stimulating Hormone